ALLOGENEIC BONE MARROW TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCY

异体骨髓移植治疗血液恶性肿瘤

• 批准号: 6269137
• 负责人: Stephen J Forman
• 金额: $ 22.12万
• 依托单位: CITY OF HOPE NATIONAL MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-18 至 1999-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6269137
• 关键词: acute lymphocytic leukemia; amphotericin B; antifungal agents; bone marrow transplantation; cell mediated lymphocytolysis test; clinical trials; cyclosporines; cytomegalovirus; disease /disorder prevention /control; ganciclovir; graft versus host disease; homologous transplantation; human subject; human therapy evaluation; methotrexate; mycosis; neoplasm /cancer therapy; polymerase chain reaction; serology /serodiagnosis; urinalysis; viral vaccines

The goal of our studies is to achieve further progress in the areas of allogeneic transplantation which would result in improved disease free survival and cure rates by a) Decreasing the leukemia relapse rate following marrow grafting; b) Reducing the incidence of acute and chronic graft-versus-host disease; c) Preventing the development of CMV associated interstitial pneumonia; and d) Decreasing the complications of the preparatory regimen. To this end we propose five clinical trials in this project entitled "Allogeneic Bone Marrow Transplantation for Hematologic Malignancy". We propose to conduct a series of Phase I, II and III trials designed to improve the efficacy and reduce the toxicity of the preparatory regimen used for patients undergoing allogeneic marrow transplantation. In addition, we will continue and extend our trials in the chemoprophylaxis of acute graft-versus-host disease after both related and unrelated bone marrow transplantation. We will also conduct trials to address the infectious complications of marrow transplantation by improving the prophylaxis of cytomegalovirus infection utilizing either pharmacologic or immunologic methods and we will explore novel approaches to the prevention of fungus infection after marrow transplantation. Four of the five specific aims will be carried out jointly at the City of Hope National Medical Center and at Stanford University. In the past, these two institutions have collaborated closely in clinical trials which have yielded promising results. The hypothesis to be tested is that the regimens described in this proposal may lead to results which are superior to those obtained with other widely utilized approaches and will increase the safety of the therapy. We have proposed prospective trials to define the role of new regimens used to ablate leukemia and prevent graft-versus- host disease and infection that have been developed from research performed by the investigators in this Program Project Grant.

我们研究的目的是在 同种异体移植将导致无疾病改善 通过a）降低白血病复发率，生存率和治愈率 跟随骨髓嫁接； b）降低急性和慢性的发生率 移植物与宿主病； c）防止与CMV相关的开发 间质性肺炎； d）减少并发症 准备方案。 为此，我们提出了五项临床试验 标题为“血液学的同种骨骨髓移植 恶性”。 我们建议进行一系列旨在的I，II和III期试验 提高功效并降低预备方案的毒性 用于接受同种异体骨髓移植的患者。 在 此外，我们将继续并扩展我们的试验在化学预防中 相关骨和无关骨骼后的急性移植物与宿主病 骨髓移植。 我们还将进行试验以解决 通过改善骨髓移植的感染并发症 使用药理或 免疫方法，我们将探索预防的新颖方法 骨髓移植后真菌感染。 五个中的四个 具体目标将在希望之城共同执行 医学中心和斯坦福大学。 过去，这两个 机构在临床试验中密切合作 产生了有希望的结果。 要检验的假设是 该提案中描述的方案可能会导致优越的结果 通过其他广泛使用的方法获得的人，并将增加 治疗的安全。 我们提出了前瞻性试验来定义 新方案用于消融白血病的作用并防止移植物与 从进行研究中开发的宿主疾病和感染 该计划项目赠款中的调查人员。